How to improve the clinical outcome of round spermatid injection (ROSI) into the oocyte: Correction of epigenetic abnormalities

Abstract Background First successful human round spermatid injection (ROSI) was conducted by Tesarik et al. in 1996 for the sole treatment of nonobstructive azoospermic men whose most advanced spermatogenic cells were elongating round spermatids. Nine offsprings from ROSI were reported between 1996...

Full description

Bibliographic Details
Main Authors: Atsushi Tanaka, Seiji Watanabe
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Reproductive Medicine and Biology
Subjects:
Online Access:https://doi.org/10.1002/rmb2.12503
_version_ 1797376210015092736
author Atsushi Tanaka
Seiji Watanabe
author_facet Atsushi Tanaka
Seiji Watanabe
author_sort Atsushi Tanaka
collection DOAJ
description Abstract Background First successful human round spermatid injection (ROSI) was conducted by Tesarik et al. in 1996 for the sole treatment of nonobstructive azoospermic men whose most advanced spermatogenic cells were elongating round spermatids. Nine offsprings from ROSI were reported between 1996 and 2000. No successful deliveries were reported for 15 years after that. Tanaka et al. reported 90 babies born after ROSI and their follow‐up studies in 2015 and 2018 showed no significant differences in comparison with those born after natural conception in terms of physical and cognitive abilities. However, clinical outcomes remain low. Method Clinical and laboratory data of successful cases in the precursor ROSI groups and those of Tanaka et al. were reviewed. Results Differences were found between the two groups in terms of identification of characteristics of round spermatid and oocyte activation. Additionally, epigenetic abnormalities were identified as underlying causes for poor ROSI results, besides correct identification of round spermatid and adequate oocyte activation. Correction of epigenetic errors could lead to optimal embryonic development. Conclusion Correction of epigenetic abnormalities has a probability to improve the clinical outcome of ROSI.
first_indexed 2024-03-08T19:35:19Z
format Article
id doaj.art-631545d3abd544c48cb2b2ada145ac1a
institution Directory Open Access Journal
issn 1445-5781
1447-0578
language English
last_indexed 2024-03-08T19:35:19Z
publishDate 2023-01-01
publisher Wiley
record_format Article
series Reproductive Medicine and Biology
spelling doaj.art-631545d3abd544c48cb2b2ada145ac1a2023-12-26T04:30:45ZengWileyReproductive Medicine and Biology1445-57811447-05782023-01-01221n/an/a10.1002/rmb2.12503How to improve the clinical outcome of round spermatid injection (ROSI) into the oocyte: Correction of epigenetic abnormalitiesAtsushi Tanaka0Seiji Watanabe1Department of Obstetrics and Gynecology Saint Mother Clinic Kitakyushu JapanDepartment of Anatomical Science Hirosaki University Graduate School of Medicine Aomori JapanAbstract Background First successful human round spermatid injection (ROSI) was conducted by Tesarik et al. in 1996 for the sole treatment of nonobstructive azoospermic men whose most advanced spermatogenic cells were elongating round spermatids. Nine offsprings from ROSI were reported between 1996 and 2000. No successful deliveries were reported for 15 years after that. Tanaka et al. reported 90 babies born after ROSI and their follow‐up studies in 2015 and 2018 showed no significant differences in comparison with those born after natural conception in terms of physical and cognitive abilities. However, clinical outcomes remain low. Method Clinical and laboratory data of successful cases in the precursor ROSI groups and those of Tanaka et al. were reviewed. Results Differences were found between the two groups in terms of identification of characteristics of round spermatid and oocyte activation. Additionally, epigenetic abnormalities were identified as underlying causes for poor ROSI results, besides correct identification of round spermatid and adequate oocyte activation. Correction of epigenetic errors could lead to optimal embryonic development. Conclusion Correction of epigenetic abnormalities has a probability to improve the clinical outcome of ROSI.https://doi.org/10.1002/rmb2.12503epigenetic abnormalityoocyte activationround spermatid injection into oocyte (ROSI)
spellingShingle Atsushi Tanaka
Seiji Watanabe
How to improve the clinical outcome of round spermatid injection (ROSI) into the oocyte: Correction of epigenetic abnormalities
Reproductive Medicine and Biology
epigenetic abnormality
oocyte activation
round spermatid injection into oocyte (ROSI)
title How to improve the clinical outcome of round spermatid injection (ROSI) into the oocyte: Correction of epigenetic abnormalities
title_full How to improve the clinical outcome of round spermatid injection (ROSI) into the oocyte: Correction of epigenetic abnormalities
title_fullStr How to improve the clinical outcome of round spermatid injection (ROSI) into the oocyte: Correction of epigenetic abnormalities
title_full_unstemmed How to improve the clinical outcome of round spermatid injection (ROSI) into the oocyte: Correction of epigenetic abnormalities
title_short How to improve the clinical outcome of round spermatid injection (ROSI) into the oocyte: Correction of epigenetic abnormalities
title_sort how to improve the clinical outcome of round spermatid injection rosi into the oocyte correction of epigenetic abnormalities
topic epigenetic abnormality
oocyte activation
round spermatid injection into oocyte (ROSI)
url https://doi.org/10.1002/rmb2.12503
work_keys_str_mv AT atsushitanaka howtoimprovetheclinicaloutcomeofroundspermatidinjectionrosiintotheoocytecorrectionofepigeneticabnormalities
AT seijiwatanabe howtoimprovetheclinicaloutcomeofroundspermatidinjectionrosiintotheoocytecorrectionofepigeneticabnormalities